Roth Capital Reiterates Their Buy Rating on Albireo Pharma Inc

By Jason Carr

In a report issued on May 18, Yasmeen Rahimi from Roth Capital reiterated a Buy rating on Albireo Pharma Inc (NASDAQ: ALBO), with a price target of $86. The company’s shares closed on Friday at $32.86.

According to TipRanks.com, Rahimi is a 4-star analyst with an average return of 33.7% and a 66.7% success rate. Rahimi covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Juniper Pharmaceuticals.

Currently, the analyst consensus on Albireo Pharma Inc is Strong Buy and the average price target is $56.33, representing a 71.4% upside.

In a report issued on May 17, Needham also assigned a Buy rating to the stock with a $50 price target.

See today’s analyst top recommended stocks >>

Based on Albireo Pharma Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.62 million. In comparison, last year the company had a GAAP net loss of $6.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Albireo Pharma, Inc. is a pharmaceutical company engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders where the improper flow or absorption of bile causes serious medical conditions.